Last reviewed · How we verify
NCT06763692
Low Intensity Focused Ultrasound for Parkinson's Disease
NA trial testing LIFU Neuromodulation in Parkinson Disease in 15 participants. Not yet recruiting.
30 March 2027
Quick facts
| Lead sponsor | Ali Rezai |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 15 |
| Start date | 1 December 2026 |
| Primary completion | 30 March 2027 |
| Estimated completion | 30 March 2028 |
Drugs / interventions tested
- LIFU Neuromodulation
Conditions studied
- Parkinson Disease — all drugs for Parkinson Disease →
Sponsor
Ali Rezai
Who can join
Adults 45 to 80, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a prospective, single-center, single-arm early feasibility study, to establish safety and tolerability of LIFU for neuromodulation in patients with parkinson's Disease
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Low-intensity transcranial ultrasound neuromodulation promotes neuronal regeneration: A new hope for noninvasive treatment of neurodegenerative diseases.
Xia S, He C, Li Y, Li H, et al · · 2026 · cited 1× · PMID 40817729 · DOI 10.4103/nrr.nrr-d-25-00113 -
Advanced Therapeutics in Parkinson's Disease: What's New?
Monje MHG, Karl JA, Cooper CS, Yomtoob J, et al · · 2026 · PMID 41706242 · DOI 10.1007/s11910-026-01483-5
Verify or expand the search:
- PubMed search for NCT06763692
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of LIFU Neuromodulation
Trials testing the same drug.
- NCT06485687 — Low Intensity Focused Ultrasound for Binge Eating Disorder · NA · active not recruiting
Other recruiting trials for Parkinson Disease
Currently open trials in the same condition.
- NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
- NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
- NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
- NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
- NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting
Other Ali Rezai trials
Trials by the same sponsor.
- NCT06485687 — Low Intensity Focused Ultrasound for Binge Eating Disorder · NA · active not recruiting
- NCT06218706 — LIFU for Treatment for Refractory Opioid Use Disorder · NA · recruiting
- NCT05997030 — Low-Intensity Focused Ultrasound (LIFU) Neuromodulation · NA · recruiting
- NCT04440891 — Application of TMS Coupled With VR for Slowing the Rate of Cognitive Decline in Patients With Alzheimer's Disease · NA · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06763692 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ali Rezai
- Last refreshed: 17 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06763692.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing